Objectives: Ciprofloxacin is the most frequently used member of the fluoroquinolones during initial eradication therapy of Pseudomonas aeruginosa, as well as during acute pulmonary exacerbations. However, its long-term effect on the susceptibility of the commensal flora within the cystic fibrosis (CF) airways has not yet been examined. The aim of this study was therefore to examine the consequence of oral ciprofloxacin usage on the resistance of the commensal viridans group streptococci (VGS), in terms of MICs and mutational analysis of the quinolone resistance-determining regions (QRDRs).
Introduction
Cystic fibrosis (CF) is the most commonly inherited fatal disease in persons originating from a white and European background, currently affecting approximately 30000 adults and children in the USA (Cystic Fibrosis Foundation; http://www.cff.org/) (11 November 2010, date last accessed). The defective gene carrying the mutation is carried in 1 in every 31 Americans (1 in 28 Caucasians), equating to more than 10 million people being a symptomless carrier of the defective gene. In the UK, CF affects approximately 8500 persons, with over 2 million people being carriers, equating to a carriage rate of the defective gene of around 1 person in 25 of the population (UK CF Trust; http://www.cftrust. org.uk/aboutcf/whatiscf/) (11 November 2010, date last accessed). In Ireland, the carriage is higher, at 1 in 19 persons in the population (Irish CF Association; http://www.cfireland.ie/ articles.php/what_is_cf) (11 November 2010, date last accessed). Further information on the prevalence of CF carriage in Europe may be found in Farrell. 1 CF is an autosomal recessive condition whereby two alleles carrying a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR) gene phenotypically manifest the disease state through a variety of multiorgan problems, associated with a pharmacological dysfunction to regulate sodium and chloride secretion across cell membranes. The most common complication of CF is the recurrence of chronic chest infections, usually caused by bacterial pathogens. 2 CF patients continue to suffer from recurrent and chronic respiratory tract infections and most of their morbidity and mortality is due to such infections throughout their life. These infections are usually dominated by Gram-negative organisms, especially by the pseudomonads, including Pseudomonas aeruginosa, Burkholderia cepacia and Stenotrophomonas maltophilia. However, with modern antibiotic management with improved antimicrobial agents, such as the aminoglycosides and carbapenems, CF patients continue to have improved survival.
Employment of the fluoroquinolones, in particular, ciprofloxacin, has now become a common treatment modality against P. aeruginosa in the management of patients with CF. Quinolones, including ciprofloxacin, are one of the few classes of orally active drugs with anti-pseudomonal activity. 3 The treatment of pulmonary exacerbations in patients chronically infected with P. aeruginosa has been demonstrated to improve forced expired volume over 1 min and, in so doing, reduce hospitalizations. However, in the UK, a resistance rate to ciprofloxacin of 30% has been observed, which means that the only option for a second antibiotic in such patients is nebulized tobramycin or colistin. 3 Nevertheless, the use of ciprofloxacin has been written into several antibiotic therapy treatment guidelines, including the UK CF Trust's guideline, 4 which cites the use of ciprofloxacin as part of the eradication regimen for up to 3 months, usually in combination with a nebulized antibiotic. In addition, where multiresistant P. aeruginosa organisms are encountered, ciprofloxacin may be commenced based on favourable disc diffusion assays, which show some activity of this agent against highly resistant organisms.
Employment of ciprofloxacin for initial eradication of P. aeruginosa and for the subsequent treatment of acute pulmonary exacerbations may therefore lead to the development of antibiotic resistance in the commensal flora of the CF patient, including viridans group streptococci (VGS), in the mouth and in the upper and lower airways. To date, there have not been any reports on the level of fluoroquinolone resistance or the molecular characterization of such resistance mechanisms, in the commensal flora of the upper respiratory tract in patients with CF, particularly in the VGS. Recently, the Streptococcus milleri group has been shown to play an important role in the pathology of lung disease, by establishing chronic pulmonary infection, where this taxon was shown to be the dominant pathogen in 39% of acute pulmonary exacerbations. 5 Hence, it was the objective of this study (i) to examine the level of resistance to ciprofloxacin in VGS isolated from CF sputum and (ii) to characterize the molecular basis for fluoroquinolone resistance in VGS, as well as in pneumococci, isolated from adult patients with CF and to assess if the use of ciprofloxacin in CF may potentially have an adverse microbiological effect elsewhere in the management of the disease.
Materials and methods

Bacterial isolates
Clinical viridans group streptococci (n ¼170) were examined in this study, as well as wild-type clinical Streptococcus pneumoniae (n¼19) and one isolate of Streptococcus agalactiae. In this study, all VGS isolates originated from 41 adult CF patients attending the Northern Ireland Regional Adult Cystic Fibrosis Unit at Belfast City Hospital during a 3 month period. Patient demographics were 21 males and 20 females, with age ranges of 21-45 years and 19-59 years, respectively. VGS isolates were obtained culturally by conventional microbiological techniques. Fresh expectorated sputum was collected from patients by physiotherapists following either inpatient or outpatient physiotherapy procedures. All sputa were plated onto selective Mitis Salivarius agar (cat. no. 229810; Becton Dickinson Ltd, Oxford, UK) containing 1% (w/v) tellurite solution and were incubated for 48 h at 378C under microaerophilic conditions in a CO 2 incubator regulated at 5% (v/v) CO 2 . Following incubation for 48 h, presumptive VGS isolates resembling small and minute blue colonies, as well as gum drop-like blue colonies and visually distinct morphological variants, were subcultured from the Mitis Salivarius agar plate from each CF patient onto Columbia blood agar (CM0331; Oxoid Ltd, Basingstoke, UK) supplemented with 5% (v/v) defibrinated horse blood for 24 h at 378C under microaerophilic conditions, as detailed above. All isolates were subsequently frozen in defibrinated horse blood (2 mL) at 2808C and stored as part of the Northern Ireland Public Health Laboratory Strain Repository. All patients from which VGS were isolated were co-colonized/co-infected with P. aeruginosa, for which they had received oral ciprofloxacin therapy consisting of 750 mg every 12 h from 3 weeks to 3 months. In addition, these patients would have received several courses of oral ciprofloxacin antibiotic therapy for 2 weeks at regular intervals for the management of their P. aeruginosa. All 
Determination of MICs
The MICs of ciprofloxacin for all isolates were determined by broth microdilution according to the CLSI standard method. 6 In order to estimate ciprofloxacin resistance, ofloxacin criteria for Streptococcus spp. other than S. pneumoniae were used. The effect of efflux pumps was examined by supplementing with 15 mg/mL reserpine. Lyophilized antimicrobial tablets were purchased from Mast Ltd (Merseyside, UK). In addition, as a comparator control population, we examined ciprofloxacin susceptibility, as above, in a non-CF population comprising 12 individuals (50 VGS isolates) who were not receiving fluoroquinolone antibiotics.
DNA extraction
Bacterial strains were subcultured on Columbia blood agar supplemented with 5% (v/v) horse blood (Oxoid Ltd) for 24 h at 378C under microaerophilic conditions. All DNA isolation procedures were carried out in a Class II Biological Safety Cabinet (MicroFlow, UK) in a room physically separated from that used to set up nucleic acid amplification reaction mixtures and also from the 'post-PCR' room in accordance with the Good Molecular Diagnostic Procedures (GMDP) guidelines of Millar et al., 7 in order to minimize contamination. Bacterial genomic DNA was extracted from a few colonies of each strain by employment of the Roche High Purity PCR Template Preparation Kit (Roche Diagnostics Ltd, Sussex, UK), in accordance with the manufacturer's instructions. Extracted DNA was stored at 2208C prior to PCR amplification.
PCR amplification of quinolone resistance-determining regions (QRDRs)
The QRDRs of gyrA, gyrB, parC and parE gene loci were amplified using four novel degenerative primer sets as described in Table 1 . For S. agalactiae, an additional primer set (parE18F and parE6R) was used (Table 1) . PCR mixtures (25 mL) contained 1 mL of DNA template, containing 25 ng of DNA, 10 mM Tris -HCl, pH 8.3, 50 mM KCl, 2.0 mM MgCl 2 , 200 mM of each dNTP, 0.6 U of Taq DNA polymerase (New England Biolabs Ltd, Hertfordshire, UK) and 10 mM of each primer. Following a hot start, the reaction mixtures were subjected to the following thermal cycling parameters in a GeneAmp PCR System 9700 Thermocycler (Applied Biosystems, Warrington, UK): 958C for 5 min; followed by 35 cycles of 958C for 30 s and annealing for 30 s (for annealing temperatures, see Table 1 ); followed by a final extension at 728C for 7 min. Following amplification, PCR products were visualized on 1.5% (w/v) agarose gels in 0.5× Tris/borate/EDTA (TBE) buffer followed by staining with ethidium bromide (0.5 mg/mL) and UV illumination with a gel image analysis system (UVP Products Ltd, Cambridge, UK).
DNA sequencing and analysis
Amplicons for sequencing were purified with a QIAquick PCR Purification Kit (QIAGEN Ltd, West Sussex, UK), according to the manufacturer's instructions. QRDRs of gyrA, gyrB, parC and parE gene sequences were determined using the BigDye Terminator Cycle Sequencing Kit and an ABI 3100 Genetic Analyzer (Applied Biosystems). Sequencing analysis was carried out using GENETYX (Genetyx Corporation, Tokyo, Japan). For phylogenetic analysis, genome sequences of S. gordonii str. Challis, S. mitis B6 and S. pneumoniae R6 were also obtained from GenBank. Phylogenetic trees were constructed by the neighbour-joining method with 1000 bootstrap replicates using MEGA 4.0.2 software.
Results
MICs and amino acid substitutions within QRDRs
Overall, 27 (27/190; 14.2%) isolates were resistant to ciprofloxacin (MICs ≥8 mg/L) and 21 (11.1%) had reduced susceptibility (MICs 4 mg/L). The remainder of the clinical isolates were susceptible to ciprofloxacin (MICs ≤2 mg/L). The MICs of ciprofloxacin, efflux activities and amino acid substitutions in the QRDRs for all ciprofloxacin-resistant isolates (MICs ≥8 mg/L; n¼27) are shown in Table 2 . Interpretation of ciprofloxacin susceptibility data is difficult when evaluating VGS organisms. Several interpretive criteria, including those of the CLSI, the BSAC and the European Committee on Antimicrobial Susceptibility Testing The primer set parE18F/parE6R was used for amplification of the parE gene in S. agalactiae. Otherwise, all primer sets were universally used to amplify gyrA, gyrB, parC and parE gene loci in each VGS species examined.
a Nucleotide positions correspond to those of S. pneumoniae R6.
Maeda et al. Table 2 , should be consulted, particularly when attempting to correlate resistance levels with QRDR mutation(s). An efflux-positive isolate was defined as an isolate with an alteration of at least one doubling dilution in MIC value. In the non-susceptible isolates, including 16 fully resistant and 14 reduced susceptibility isolates, inhibition of efflux activity resulted in a 2-to 4-fold decrease in MIC. There were 14 substitution positions, including six positions that corresponded to previously reported mutations responsible for quinolone resistance. Eight novel potential QRDR resistance mutations were found in this study. Double mutations in gyrA and parC/parE led to MICs of 16 to .64 mg/L, while single mutations in parC or parE resulted in MICs of 8-32 mg/L and 8 mg/L, respectively. At the same time, there were eight non-susceptible strains with MICs ranging from 4 mg/L to 64 mg/L, which showed neither efflux activity nor any amino acid substitution in the QRDRs. In comparison with S. pneumoniae R6, 67 amino acid substitutions having no effect on ciprofloxacin susceptibility were found (Tables 3 and 4 ). These substitutions were common within a single VGS species or shared by more than one species and 94.0% were unique to VGS species and S. agalactiae. In addition, 35 spontaneous amino acid substitutions were found from susceptible strains, which are listed in Table 5 . QRDR sequences of four genes from 14 streptococcal species have subsequently been deposited in GenBank, under the accession numbers detailed in Table 6 . In the CF patient population from which the VGS were obtained for this study, 15 patients were infected with P. aeruginosa that was resistant to ciprofloxacin. In comparison, none of the non-CF VGS organisms from the comparator control population was resistant to ciprofloxacin, but 42% showed intermediate resistance.
Phylogenetic analysis
The mean similarities of each species to S. pneumoniae R6 were: gyrA, 70.3% -95%; gyrB, 69.6% -96.2%; parC, 76.1% -94.8%; and parE, 70.7% -94.7% (Table 7 ). The close relatives of S. pneumoniae, S. mitis and S. oralis, showed high similarity for all four genes (more than 86%). In contrast, distant species, such as S. agalactiae, had lowest similarity (69.6% -77.1%). A phylogenetic tree of gyrA and gyrB showed a distinctive cluster within each species, except for S. mitis and S. pneumoniae (Figure 1a and b) . However, parC and parE made mosaic clusters (Figure 1c and d) . With regard to the parC tree, S. cristatus made a cluster together with S. gordonii and S. sanguinis. S. oralis formed two clusters, one close to S. mitis and the other close to S. infantis. Again, in the case of parE, S. cristatus was grouped with S. gordonii and S. sanguinis. There were a few outliers, including two S. oralis in the S. mitis -S. pneumoniae cluster, including one for gyrA (C12) and one for parC (C206), and another two S. oralis (C56, C142) and one S. mitis (C54) in the S. infantis cluster of parE. Three strains constantly grouped together within the S. infantis species, including S. mitis C106 and C181 and S. pneumoniae C69. Table 3 . Silent amino acid substitutions in the QRDRs of DNA gyrase that had no effect on ciprofloxacin susceptibility V .
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Amino acid positions correspond to those of S. pneumoniae R6.
Bold formatting denotes previously reported substitution positions.
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Discussion
There is increasing evidence that suggests that VGS organisms are donors of quinolone resistance gene determinants to pneumococci, as defined through sequence analysis and in vitro transformation experiments.
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The spontaneous mutation frequency of ciprofloxacin resistance in S. pneumoniae has been reported as 9×10 27 to 8.5×10
28
, while the transformation frequency of S. pneumoniae and chromosomal DNA of quinolone resistance mutants, S. mitis, S. oralis, S. sanguinis and Streptococcus constellatus, is 5×10
23
, 1×10
, 5×10
25 and ,10 27 , respectively. 10, 11 Amino acid substitutions in QRDRs of DNA gyrase and DNA topoisomerase IV, encoded by gyrA, gyrB, parC and parE, and efflux pumps are responsible for such resistance. 12 Early investigations have demonstrated that topoisomerase IV is the primary target and gyrase is the secondary target, with parC then gyrA being target genes for ciprofloxacin resistance in S. pneumoniae. 13 Very few studies have been conducted on the QRDRs of VGS species, especially in those species that are not close relatives of S. pneumoniae. Therefore, it remains unclear what amino acid substitutions in QRDRs of VGS species have a similar effect on quinolone resistance as in pneumococci. This study investigated QRDRs of ciprofloxacin-resistant VGS originating in a patient population with a high therapeutic exposure to this antibiotic, and examined the phylogenetic relationships of the QRDRs of gyrA, gyrB, parC and parE genes among the VGS species.
In order to characterize QRDR mutations in VGS organisms, we initially attempted to use pre-existing QRDR primer sets for S. pneumoniae 14 to allow us to amplify these regions in VGS/nonpneumococcal organisms. These attempts failed to reliably amplify similar regions (gyrA, gyrB, parC and parE) in the majority of VGS species tested, suggesting divergence between sequence homology at the primer regions between pneumococci and VGS species. As a result, we designed in silico four novel PCR assays for these loci in VGS, as well as for S. agalactiae, which successfully facilitated amplification of the QRDRs of the four gene loci, thus allowing sequence analyses of resulting sequence data.
In this study, we describe novel QRDR mutations of VGS, especially in S. infantis and S. parasanguinis, which have not been reported before. Although these mutations were observed at the same position as an established quinolone resistance mutation, this is the first occasion when these mutations have been described in VGS and other than in pneumococci. Table 4 . Silent amino acid substitutions in the QRDRs of DNA topoisomerase IV that had no effect on ciprofloxacin susceptibility Bold formatting denotes previously reported substitution positions. a   GyrA  T56S, M99V, K127R, I128F, I136L, K138T, V144T, R152H,  L155V/M, L164I, P181R, G186A/S, T188I, P199T, K204R  GyrB  Q375V, N423D, E448D, A472S, F491I, V493I  ParC  T54A, F55Y, I69V, E100V, N105K, G128D, 
JAC
On closer examination, we were able to identify an emerging trend of mutation type. None of the isolates had a single gyrA mutation; however, a single parC mutation was observed in 13 isolates. Moreover, only two isolates had a double mutation in gyrA and parC and exhibited MICs of 16 and 32 mg/L. These results fit into previous observations that parC is the primary target and the mutation is a trigger of low-level resistance, whilst a double mutation occurring with gyrA causes high-level resistance. 12, 13 Those isolates that showed MICs ≥64 mg/L possessed a gyrA and parC double mutation and either a gyrB mutation (Ser466Tyr) or mutations in both gyrB (Glu406Val) and parE (Lys407Glu). The mutation Ser466Tyr in gyrB seemed to have zero effect on ciprofloxacin resistance, but, because of limited data, it is too early to make a definitive judgement on this. Mutations in parC were usually associated with an MIC of at least 8 mg/L, with the exception of isolate C158, which had an MIC of 4 mg/L. Equally, we were unable to distinguish whether or not the mutations Glu406Val in gyrB and Lys407Glu in parE had any effect on high-level ciprofloxacin resistance.
One interesting finding from this study was the identification of eight non-susceptible isolates, which did not have a reserpinesensitive efflux system or any amino substitutions. These may be due to either a reserpine ineffective efflux system and/or substitutions lying outside the QRDRs. 15 Adam et al. 15 have described ciprofloxacin-resistant pneumococci that had neither amino acid substitutions nor efflux activity. Although they were unable to define whether the phenomenon was due to another efflux system, due to the lack of gyrB sequence information, we believe that the unexplained fluoroquinolone resistance in our study is more likely to be due to efflux system(s). Recent studies have discovered novel efflux systems mediated by PatA and PatB proteins through transcriptome assays. 16, 17 These efflux systems can also be inhibited by reserpine, unlike the PmrA efflux system, which used to be considered the only efflux system mediating quinolone resistance. 18, 19 Hence, there may be an additional reserpine-resistant efflux system at work, which as yet has not been characterized. However, it has not been confirmed that this novel efflux system can cause highlevel resistance, which we saw in this study. Therefore, we assume there may be other quinolone resistance mechanisms at play with these small numbers of isolates, such as plasmidmediated quinolone resistance in Gram-negative bacteria, 20 which we have not seen, as yet, in VGS.
We found smaller numbers of common amino acid substitutions in parC and parE than in gyrA and gyrB, and hence the phylogenetic tree of parC and parE has a more complicated structure. Unlike gyrA and gyrB, those species belonging to the mitis group made mosaic clusters, especially S. infantis, S. mitis, S. oralis and S. pneumoniae, and also S. cristatus, S. gordonii and S. sanguinis. Previously, Humbert et al. 21 described successful transformation between S. pneumoniae and cloned divergent Although we do not know the reason for differences between gyrase genes and topoisomerase genes, these results suggest that the heterogeneity of the phylogenetic tree may be due to natural recombination events. The few outliers of S. oralis may be the result of possible genetic exchange between S. mitis of gyrA and either S. mitis or S. pneumoniae of parC. Janoir et al. 10 showed the transformation frequency was 10 26 when they conducted a transformation experiment with fluoroquinolone-resistant S. pneumoniae chromosomal DNA and wild-type S. oralis. This frequency was not as high as in the reciprocal experiments they conducted (5×10 25 ). In the natural environment, we do not know how frequently genetic exchange occurs among species within the genus Streptococcus. Therefore, there is a possibility that, with the QRDRs, all four gene loci have been modified by recombinational events, as we saw in three isolates (C69, C106 and C181). This may have been due to competence-stimulating peptide (CSP), which can induce competence for transformation of S. pneumoniae and S. mitis, which has been described previously. 22 Overall, in our study, we saw a marked increase in fluoroquinolone resistance amongst a relatively large population of VGS organisms isolated from adult CF patients who would have had multiple exposures to oral ciprofloxacin as part of their antibiotic management for their chronic P. aeruginosa airways infection. We subsequently wished to compare our CF VGS population, which originated from adult CF patients who had received various exposures to oral ciprofloxacin at several periods in the antibiotic management of their CF pseudomonal lung infections, with a VGS population from a non-CF patient group, which had not been recently exposed to any oral fluoroquinolone agents. As a comparator, clinically non-significant and non-invasive VGS organisms were examined in 12 consecutive patients in the community who were attending their primary care doctor, and we did not detect resistance in these patients' VGS isolates to ciprofloxacin. These data therefore suggest that continued exposure to ciprofloxacin in the CF patient population may lead to increased levels of ciprofloxacin resistance in the CF VGS commensal flora. In order to assess the rate of resistance, we selected a comparator of similar VGS organisms from non-CF patients in the community, who did not have any recent exposure to fluoroquinolone usage. When we examined 50 VGS from this patient population using the same MIC methodology, the ciprofloxacin resistance fell to only 8%, where these isolates had an MIC of 4 mg/L, hence defining these organisms as intermediate resistant (data not shown). Hence, we consider that the exposure, duration of exposure and frequency of exposure of CF patients to ciprofloxacin does have an adverse consequence for VGS resistance rates.
VGS are not considered primary pathogens of the respiratory tract in patients with CF and the consequence of the presence of these organisms in the lower airways of these patients is largely unknown. Selection of fluoroquinolone-resistant VGS during ciprofloxacin therapy is a frequent treatment side effect that cannot be prevented when ciprofloxacin is being used to treat resistant P. aeruginosa. Treatment of P. aeruginosa with oral ciprofloxacin in patients with CF may therefore concurrently reduce antibiotic susceptibility in the commensal VGS flora, where these organisms may potentially act as a reservoir of fluoroquinolone resistance gene determinants for newly acquired and antibiotic-susceptible pathogens, particularly the S. milleri group, as well as in S. pneumoniae.
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